Skip to content
GLP-1 Scorecard
Menu
Site position #6

RxSpan MD

By Dana WhitfieldUpdated

RxSpan MD offers compounded injections, oral options and a brand-name lane, with regular monthly pricing alongside discounted prepaid plans that require a closer look at renewal and refund terms.

Our take

RxSpan MD is worth comparing if you want several GLP-1 formats in one physician-reviewed service. The best advertised rates come with prepaid multi-month plans, so the regular monthly offer is the better starting point for a shopper who has not tried the service. Compounded programs remain on its current public menu.

Visit RxSpan MD ↗We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Semaglutide
$249/mo month-to-month ($219 on three months, $199 on six, $194 on twelve)
Tirzepatide
$329/mo month-to-month ($309 on three months, $289 on six, $269 on twelve)
Coverage
Confirm treatment availability during intake
Brand-name
Yes

Weigh RxSpan MD against the full graded field on the best semaglutide providers scorecard, or line it up against its closest alternatives.

The rendered catalog lists regular monthly compounded injections at $249 for semaglutide and $329 for tirzepatide. Lower headline equivalents depend on a prepaid term and promotional code; the total payment and renewal matter more than the divided monthly figure.

Compounded treatment is still on the current menu

RxSpan’s current homepage advertises compounded and brand-name GLP-1 programs. Its public weight-loss catalog offers semaglutide and tirzepatide injections alongside oral options. A past observation that compounded treatment had disappeared does not describe the menu reviewed on October 6, 2026.

That breadth is useful for comparing service options, but it is not evidence that the formulations are interchangeable. The prescription decision belongs to the clinician. Choose the service for the option actually proposed for you, rather than assuming that every product on a broad menu would be appropriate.

Start with the regular monthly number

The rendered injection offers show $249 for regular monthly semaglutide and $329 for regular monthly tirzepatide. Semaglutide also lists $219 a month on three months and $199 on six months. The current annual promotions advertise rounded equivalents of $175 and $243, tied to prepaid totals of $2,094 and $2,905 respectively with STARTNOW. The annual offers also state automatic renewal.

The catalog says the price includes the consultation, medication, supplies, shipping and support. That helps define the purchase, but a monthly equivalent still is not a monthly payment. Before selecting a long plan, compare the total due, the amount of medication supplied at each shipment and the next renewal charge. Those details determine the commitment.

A cancellation promise leaves a refund question

The catalog says patients can cancel or change their plans. The public Terms of Service, dated June 3, 2026, requires payment of applicable fees but does not set out a detailed refund schedule for unused prepaid treatment. Neither statement establishes that canceling halfway through a longer plan returns the remaining balance.

That is why I would begin the comparison with the regular monthly option. A large advance payment should buy a clearly understood saving, not uncertainty about what happens if the clinician changes the plan or treatment stops. Ask specifically about unused prepaid months, future renewals and any fee if no prescription is issued. This review did not complete intake or obtain a patient-specific quote.

Named leadership helps, but it does not identify your prescriber

The company names Dr. John Diaz, a board-certified plastic surgeon, as its founder. It promises licensed-physician review, messaging and appointments with the care team, and free expedited delivery. The terms explain that healthcare providers on the platform are independent professionals responsible for the medical care.

Those are useful disclosures. They do not establish who will personally review your case, how quickly a clinical question will be answered or which pharmacy will dispense a particular prescription. My recommendation remains conditional on those practical answers and a clear prepaid refund policy. The range of options earns attention; the annual headline alone does not earn a commitment.

Factor breakdown

Each of the six graded dimensions. See the methodology.

Cost value86/100
Dose & formulation89/100
Clinical oversight88/100
Labs & monitoring83/100
Fulfillment89/100
Contract terms53/100

Strengths

  • Public catalog offers compounded injections, oral options and brand-name programs
  • Regular monthly injection pricing of $249 semaglutide and $329 tirzepatide
  • Catalog states consultation, medication, supplies, shipping and support are included
  • Names physician founder Dr. John Diaz and describes licensed-physician review

Where it loses points

  • Lowest advertised monthly equivalents require prepaid terms and a promotional code
  • Annual promotions automatically renew
  • Public terms do not establish a refund schedule for unused prepaid treatment
  • Compounded semaglutide and tirzepatide are not FDA-approved

Bottom line — Grade B

Best for: Shoppers comparing injectable and oral options who are willing to check the selected term, renewal and total payment before enrolling.

Look elsewhere if: Anyone choosing solely on the lowest monthly equivalent, or expecting cancellation to guarantee a refund of a prepaid plan.

Site position #6 of 542. Commercial relationships affect placement, not the score. See our featured provider, CoreAge Rx (#1), for comparison.

Closest here

The rankings grading nearest RxSpan MD — the realistic shortlist.

The 18 rankings nearest this one

View full scorecard rankings →

Pricing/verification reflect RxSpan MD's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on RxSpan MD's site. Not medical advice; see our disclosure.

← Back to the scorecard